- Home
- DXR
as 12-20-2024 4:00pm EST
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
| Founded: | 1970 | Country: | United States |
| Employees: | N/A | City: | NEW YORK |
| Market Cap: | 42.6M | IPO Year: | N/A |
| Target Price: | $24.75 | AVG Volume (30 days): | 23.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.35 | EPS Growth: | -57.75 |
| 52 Week Low/High: | $7.19 - $10.04 | Next Earning Date: | 01-01-0001 |
| Revenue: | $154,205 | Revenue Growth: | -13.06% |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Daxor Corporation (DXR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Michel Robert J | DXR | Chief Financial Officer | Dec 6 '24 | Buy | $0.00 | 4,750 | $0.00 | 15,050 | |
| Feldschuh Jonathan Adam | DXR | Chief Scientific Officer | Dec 6 '24 | Buy | $0.00 | 32,000 | $0.00 | 35,908 | |
| Feldschuh Michael Richard | DXR | Chief Executive Officer | Dec 6 '24 | Buy | $0.00 | 45,000 | $0.00 | 207,492 |
Latest Daxor Corporation News
DXR Breaking Stock News: Dive into DXR Ticker-Specific Updates for Smart Investing
GlobeNewswire
5 days ago
Daxor Expands Its BVA-100™ Blood Volume Diagnostic to Two New Hospital Systems Adding to Sales Momentum
GlobeNewswire
2 months ago
DAXOR'S INNOVATIVE BVA-100™ BLOOD VOLUME DIAGNOSTIC FEATURED AT MEDAXIOM CV TRANSFORUM FALL '24
GlobeNewswire
2 months ago
Daxor Corporation to Participate in a Fireside Chat at the 2024 Maxim Healthcare Virtual Summit
GlobeNewswire
3 months ago
Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device
GlobeNewswire
3 months ago
Daxor Corporation to Exhibit at the Heart Failure Society of America Annual Scientific Meeting 2024
GlobeNewswire
3 months ago
Newly Published Review Highlights the Pivotal Role of Daxor’s Blood Volume Analysis Technology in Advancing Cardiorenal Syndrome Management
GlobeNewswire
4 months ago
Daxor Corporation Receives $300K Matching Fund Award From Launch Tennessee
GlobeNewswire
4 months ago
Leading Central Florida Hospital Implements Daxor’s BVA-100™ Blood Volume Diagnostic for Heart Failure Patient Care
Compare DXR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DXR Daxor Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.